Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07342439 · ClinicalTrials.gov registry record · Phase 3
Study of Serine Supplementation to Protect Vision in MacTel
A Phase 3 study, sponsored by The Lowy Medical Research Institute Limited.
- Not yet
- Registry status
- Phase 3
- Development phase
- 120
- Enrollment target
NCT07342439 is a Phase 3 study that has not yet begun recruiting, run by The Lowy Medical Research Institute Limited. The registered enrollment target is 120 participants.
The verdict
NCT07342439, a Phase 3 study, has not yet begun recruiting, sponsored by The Lowy Medical Research Institute Limited.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 120 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to look at the efficacy and safety of giving oral serine (an amino acid) on the progression of structural and functional changes of the retina in people with MacTel type 2. The main questions it aims to answer are: * Does serine slow the progression of MacTel? * Is long-term serine supplementation safe in people with MacTel? Researchers will compare serine to a placebo (a look-alike substance that contains no drug) to see if serine works to slow the progression of MacTel. Participants will: * Take serine or a placebo twice a day for 24 months * Visit the clinic once every 6 months for eye exam, eye imaging and blood tests * Keep a diary of their symptoms, missed doses, and changes in medications
Interventions
- OTHER Placebo
- DRUG L-serine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2026-09 |
| Est. Completion | 2030-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07342439
The ClinicalTrials.gov registry entry for NCT07342439 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Lowy Medical Research Institute Limited, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07342439 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07342439 about?
NCT07342439 is a clinical study titled "Study of Serine Supplementation to Protect Vision in MacTel". The goal of this clinical trial is to look at the efficacy and safety of giving oral serine (an amino acid) on the progression of structural and functional changes of the retina in people with MacTel type 2. The main questions it aims to answer are: * Does serine slow the progression of MacTel? * I...
What is the current status of trial NCT07342439?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2026-09. Estimated completion is 2030-02.
What interventions are being tested in trial NCT07342439?
The interventions under investigation include: Placebo (OTHER), L-serine (DRUG).
Who is sponsoring clinical trial NCT07342439?
This trial is sponsored by The Lowy Medical Research Institute Limited, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.